Comparison · NCT00726453-sae
Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events. Trial comparisons, record NCT00726453-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00726453-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.363 | 0.338 | 0.389 | wilson | |
| Risk in group 2 | 0.623 | 0.531 | 0.706 | wilson | |
| Risk difference, group 1 minus group 2 | -0.26 | -0.347 | -0.165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.583 | 0.497 | 0.683 | log | |
| Odds ratio, group 1 over group 2 | 0.345 | 0.233 | 0.512 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Primary Enrollment Group than on 38 mm Length Sub-Study | 3.85 | 2.88 | 6.07 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Primary Enrollment Group | All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. Patients were assigned in to one of four sub-studies based on the stent required:~2.25 mm - 3.5 mm Main study, 2.25 mm - 3.5 mm Angio/IVUS Sub-study, 4.0 mm Sub-study and are collectively referred to as the Primary Enrollment Group (PEG). | 509 | 1,402 | EG000 |
| Group 2 | 38 mm Length Sub-Study | All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. Patients were assigned in to one of four sub-studies based on the stent required this group is the 38 mm Length Main study. Enrollment in this group opened after the Primary Enrollment Group had closed. | 71 | 114 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 12 months
Source ClinicalTrials.gov
Trial
- Title
- The Medtronic RESOLUTE US Clinical Trial
- NCT number
- NCT00726453
- Phases
- NA
- Conditions
- Coronary Artery Disease
- Interventions
- Resolute Zotarolimus-Eluting Coronary Stent
- Lead sponsor
- Medtronic Vascular
- Results first posted
- 2012-05-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00726453?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00726453-sae